TW201412985A - Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells - Google Patents

Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells Download PDF

Info

Publication number
TW201412985A
TW201412985A TW101134035A TW101134035A TW201412985A TW 201412985 A TW201412985 A TW 201412985A TW 101134035 A TW101134035 A TW 101134035A TW 101134035 A TW101134035 A TW 101134035A TW 201412985 A TW201412985 A TW 201412985A
Authority
TW
Taiwan
Prior art keywords
cell
gene
cells
ipab
protein
Prior art date
Application number
TW101134035A
Other languages
Chinese (zh)
Other versions
TWI472617B (en
Inventor
Jiann-Hwa Chen
Chao-Chieh Tseng
Original Assignee
Nat Univ Chung Hsing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Chung Hsing filed Critical Nat Univ Chung Hsing
Priority to TW101134035A priority Critical patent/TWI472617B/en
Publication of TW201412985A publication Critical patent/TW201412985A/en
Application granted granted Critical
Publication of TWI472617B publication Critical patent/TWI472617B/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention discloses protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells. By IpaB or IpaB803 gene transfection on a cell, IpaB or IpaB803 protein will express in the cell. Followed by co-cultured with a macromolecule, it is found that a macromolecule may enter the cytoplasm or/ and nucleus.

Description

調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法 A protein that regulates the entry of macromolecules into cells and a method for regulating the entry of macromolecules into cells

本發明係有關於大分子運送至細胞之方法,特別係指一種調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法。 The present invention relates to a method for transporting macromolecules to cells, and more particularly to a method for regulating the entry of macromolecules into cells and the regulation of macromolecules into cells.

按,真核細胞係具有細胞膜、細胞核、膜內胞器以及細胞質液等,其中,細胞膜係為細胞內外環境之雙層磷脂膜,其上鑲嵌有各種不同功能之膜蛋白以及與膜蛋白結合之醣類,而形成一種有選擇性之通透膜。細胞膜上具有孔隙,而得與周圍環境進行物質交換或是信息傳遞,透過孔隙以及膜蛋白之性質,達到調節物質進出細胞內外之功能,以維持細胞內之穩定性。而細胞核係為存在於細胞中之一封閉式膜狀胞器,內部含有細胞中大多數之遺傳物質,外部則有完全包覆細胞核之核膜,而將胞內物質與細胞質等分隔。核膜亦為雙層磷脂膜,分為核心膜與外核膜,其上具有核孔(nuclear pore complexes,NPCs),孔徑約為50~100nm,而用以供分子自由擴散之孔徑只有9nm,用以控制物質進出細胞核與細胞質間。 According to the eukaryotic cell line, the cell membrane, the nucleus, the intracellular membrane, and the cytosol, etc., wherein the cell membrane is a bilayer phospholipid membrane inside and outside the cell, which is embedded with membrane proteins of various functions and combined with membrane proteins. Sugars form a selective permeable membrane. There are pores on the cell membrane, and the material exchange or information transmission with the surrounding environment, through the pores and the nature of the membrane protein, can regulate the function of the substances entering and leaving the cells inside and outside, in order to maintain the stability within the cells. The nucleus is a closed membranous organelle present in the cell, which contains most of the genetic material in the cell, and the outer part completely covers the nuclear membrane of the nucleus, and separates the intracellular substance from the cytoplasm. The nuclear membrane is also a double-layer phospholipid membrane, which is divided into a core membrane and an outer nuclear membrane, which have nuclear pore complexes (NPCs), a pore size of about 50-100 nm, and a pore diameter of only 9 nm for free diffusion of molecules. It is used to control the entry and exit of substances between the nucleus and the cytoplasm.

胞外小分子物質能夠透過擴散或滲透之被動運輸、或是藉由膜上蛋白質之主動運輸而穿過孔隙送入胞內,而大分子物質,如細菌或是病毒等,則無法通過細胞膜進入細胞內,需要藉由細胞之吞噬作用或是胞飲作用而進入細胞。而位於細胞質中之小型水溶性分子或是離子和小於40 kDa之蛋白質可藉由被動運輸或是擴散作用直接通過核膜而進入細胞核中,但超過40 kDa之蛋白質或是核酸等較大分子則需要 藉由自身之進核訊號(nuclear localization signal,NLS)以及輸入蛋白α/β(importin α/β)複合物之交互作用,才能經過核孔而進入細胞核中。 Extracellular small molecules can be transported through the pores through the passive transport of diffusion or infiltration, or through the active transport of proteins on the membrane, while macromolecular substances such as bacteria or viruses cannot enter through the cell membrane. In the cell, it is necessary to enter the cell by phagocytosis or pinocytosis of the cell. Small water-soluble molecules or ions in the cytoplasm and proteins less than 40 kDa can enter the nucleus directly through the nuclear membrane by passive transport or diffusion, but larger proteins such as proteins or nucleic acids over 40 kDa need Through the interaction of the nuclear localization signal (NLS) and the input protein α/β (importin α/β) complex, it can enter the nucleus through the nuclear pore.

詳言之,進核訊號序列係由數個帶正電之鹼性胺基酸離胺酸(lysine)及精胺酸(arginine)組成者(Robbins et al.,1991),暴露於蛋白之表面。因此,位於細胞質中之物質必須本身攜帶進核訊號,而被細胞核膜上之輸入蛋白α/β所組成之接受器所辨認並交互作用,使帶有進核細胞之蛋白質能經由核孔而被送入細胞核中(Lange et al.,2007)。目前文獻中已揭露菸草嵌紋病毒(Tobacco MosaicVirus,TMV)的複製酵素(Figueire et al.,2002)、穿梭性蛋白如HsfA2蛋白(Scharf et al.,1998;Heerklotz et al.,2001),分別具有進核訊號之序列。是以,不具有進核訊號之大分子,則必須藉由外來載體或是外力幫忙才能夠進入細胞內,而具有進核訊號之大分子則能本身直接進入細胞內。 In detail, the nuclear signal sequence into a plurality of lines of the positively charged basic amino acids lysine (lysine) and arginine (Arginine) composed by (Robbins et al., 1991) , exposed to the surface proteins . Therefore, the substance located in the cytoplasm must carry the nuclear signal itself, and be recognized and interacted by the receptor composed of the input protein α/β on the nuclear membrane, so that the protein with the nucleated cells can be passed through the nuclear pore. Into the nucleus (Lange et al ., 2007). Tobacco Mosaic Virus (TMV) replication enzymes (Figueire et al ., 2002) and shuttle proteins such as HsfA2 protein (Scharf et al., 1998; Heerklotz et al., 2001) have been disclosed in the literature. A sequence with a nuclear signal. Therefore, a macromolecule that does not have a nuclear signal must be assisted by a foreign carrier or external force to enter the cell, and a macromolecule with a nuclear signal can directly enter the cell itself.

目前臨床醫學上對於癌症或遺傳性疾病等疾病之治療方式除了以藥物或是化療等方式加以控制外,目前許多研究皆致力開發載體或是利用套組而應用於基因治療上,亦即將藥物、蛋白質或是去氧核糖核酸等大分子物質直接送入細胞質或/及細胞核中,而使該被送入細胞核之物質於細胞內發揮功效或是殺死細胞。目前使用之載體係可分為兩類,其一為病毒載體,如反轉錄病毒、腺病毒等,另一為非病毒載體,如裸露DNA(naked DNA)、微脂粒等,惟,該兩類載體分別具有其缺點如下: At present, in clinical medicine, treatment of diseases such as cancer or hereditary diseases is controlled by drugs or chemotherapy. At present, many studies are devoted to the development of vectors or the use of kits for gene therapy, that is, drugs, Macromolecules such as proteins or deoxyribonucleic acids are directly delivered into the cytoplasm or/and nucleus, so that the substance that is introduced into the nucleus functions in the cell or kills the cell. The vectors currently used can be divided into two types, one is a viral vector, such as a retrovirus, an adenovirus, etc., and the other is a non-viral vector, such as naked DNA, vesicles, etc., but the two Class carriers have their disadvantages as follows:

以病毒載體而言,病毒雖可以自行感染細胞,為一種效率高之基 因傳送系統,然病毒本身之致病性或致癌性,必須經過處理後才能使用;再者,病毒係僅能用以攜帶目標基因,並該目標基因之大小有所限制,使用上不僅安全性有所欠缺,且應用範圍也被受限;另以非病毒載體而言,雖然安全性較病毒載體好,但傳遞物質之效率不佳,實用性與效益無法達到預期。 In the case of viral vectors, the virus can infect cells by itself, which is an efficient base. Due to the transmission system, the pathogenicity or carcinogenicity of the virus itself must be treated before it can be used. Furthermore, the virus system can only be used to carry the target gene, and the size of the target gene is limited, and the use is not only safe. There are some shortcomings, and the scope of application is also limited; in addition, in terms of non-viral carriers, although the safety is better than the viral carrier, the efficiency of delivering the substance is not good, and the practicality and benefit cannot be expected.

綜上所述,目前之載體系統,除了無法兼顧安全性以及實用性之外,並且必須將欲送入之物質與載體合為一體,始能將物質送入標的細胞中。因此,開發一兼具安全及實用之運送系統,而使大分子能夠進入到細胞內,發揮其作用,乃係目前生物醫學研究所迫切需要者。 In summary, the current carrier system, in addition to the inability to balance safety and practicality, must integrate the substance to be fed into the carrier and then deliver the substance into the target cells. Therefore, the development of a safe and practical transport system that allows macromolecules to enter the cell and play its role is urgently needed by the current biomedical research institute.

本發明之主要目的即在於提供一種使大分子進入細胞內之方法,包含有下列步驟:(A)構築一重組質體,具有一外源基因,得用以表現至少包含有一段帶正電之鹼性胺基酸序列之蛋白,該胺基酸序列編碼為KKKL;(B)將該重組質體轉殖至一真核細胞內,而使該外源基因於該真核細胞內表現;(C)選取一大分子,與步驟B中之該真核細胞共同培養;(D)該大分子進入到該細胞內,其中: The main object of the present invention is to provide a method for introducing macromolecules into cells, comprising the steps of: (A) constructing a recombinant plastid having an exogenous gene, which is used to represent at least one positively charged one. a protein of a basic amino acid sequence, the amino acid sequence encoding KKKL; (B) transducing the recombinant plastid into a eukaryotic cell, and allowing the foreign gene to be expressed in the eukaryotic cell; C) selecting a large molecule, co-cultured with the eukaryotic cell in step B; (D) the macromolecule enters the cell, wherein:

步驟A中之該外源基因係為IpaB基因或及IpaB基因衍生產物。 The exogenous gene in step A is the IpaB gene or the IpaB gene derivative product.

步驟D中所選定之該大分子係得為一細菌,如福氏桿菌(Shigella flexneri,S.flexneri)、大腸桿菌等,得以進入該真核細胞中之細胞質及/或細胞核內。 The macromolecule selected in step D is obtained as a bacterium, such as Shigella flexneri (S. flexneri ), Escherichia coli, etc., into the cytoplasm and/or nucleus of the eukaryotic cell.

本發明之另一目的係在於提供一種調控大分子進入細胞內之蛋白質,其胺基酸序列係至少包含一段帶正電之鹼性胺基酸序列而為 KKKL。更進一步而言,該調控大分子進入細胞內之蛋白質係由IpaB基因或IpaB基因衍生產物所轉譯表現者。 Another object of the present invention is to provide a protein for regulating the entry of macromolecules into cells, wherein the amino acid sequence comprises at least a positively charged basic amino acid sequence. KKKL. Further, the protein that regulates the entry of the macromolecule into the cell is expressed by the IpaB gene or the IpaB gene-derived product.

以下將藉由若干實例並搭配圖式更進一步說明本發明如後。 The invention will be further illustrated by the following examples in conjunction with the drawings.

更進一步說明本發明於下列實例中所用到之生物材料之簡稱。 The abbreviation of the biological material used in the following examples of the present invention is further explained.

IpaB蛋白,為入侵質體抗原B(Invasion plasmid antigen B)之縮寫,其係為福氏桿菌攜帶之毒性質體經由第三型分泌系統所分泌者。IpaB蛋白係由IpaB基因所轉譯者,大小為62.1kDa(580個胺基酸),而IpaB基因係位於毒性質體上之ipa-mxi-spa(invasion plasmid antigen、Membrane expression of Ipa and Surface presentation of Ipa Antigens)區域,基因長度為1743 bp。 The IpaB protein is an abbreviation for Invasion plasmid antigen B, which is secreted by the genus of the genus Fusarium via the third-type secretory system. The IpaB protein is a transposon of the IpaB gene, which is 62.1 kDa (580 amino acids), while the IpaB gene is located on the virulence of the ipa-mxi-spa (invasion plasmid antigen, Membrane expression of Ipa and Surface presentation of In the Ipa Antigens region, the gene length is 1743 bp.

本發明中所採用之IpaB蛋白係為福氏桿菌野生株SH2308所表現者,其中,福氏桿菌野生株SH2308係為本案發明人於先前研究中所發現一株會表現IpaB蛋白之菌株,並將菌株SH2308之IpaB基因進行定序,得到核苷酸序列編碼為SEQ ID NO:1。。將菌株SH2308之IpaB基因與已發表於美國國立生物技術信息中心(National Center for Biotechnology Information;NCBI)之兩個福氏桿菌(S.flexneri)毒性質體(Accession:NC_004851.1;Accession:NC_002698.1)內之IpaB基因比對,發現在第52和507個鹼基之位置有分別由A變成T及由T變成A,即於第52鹼基位置之差異使轉譯出來之胺基酸由蘇胺酸(Threonine)變成丙胺酸(Alanine),在第507鹼基位置之差異係未有造成轉譯出來之胺基酸有所不同。上述差異不影響本發明所採用之 IpaB蛋白與上述已發表之兩IpaB蛋白,二者之第175~178胺基酸序列皆為KKKL,為一段帶正電之鹼性胺基酸序列。 The IpaB protein used in the present invention is represented by the wild type strain SH2308 of Fusarium, wherein the wild type strain SH2308 is a strain which the inventor of the present invention found in the previous study to express the IpaB protein, and The IpaB gene of strain SH2308 was sequenced, and the nucleotide sequence was obtained as SEQ ID NO: 1. . The IpaB gene of strain SH2308 and have been published in the US National Center for Biotechnology Information (National Center for Biotechnology Information; NCBI ) two of Freund's bacillus (S.flexneri) toxicity plasmid (Accession: NC_004851.1; Accession: NC_002698 . 1) IpaB gene alignment in the 1st, found that the position of the 52nd and 507th bases changed from A to T and from T to A, respectively, that is, the difference in the 52nd base position makes the translated amino acid from Su The amino acid (Threonine) becomes alanine, and the difference at the 507th base position does not cause the amino acid to be translated to be different. The above difference does not affect the IpaB protein used in the present invention and the above-mentioned two IpaB proteins, and the 175-178 amino acid sequence of both is KKKL, which is a positively charged basic amino acid sequence.

IpaB803蛋白,係由本發明所採用之IpaB基因自ATG起始密碼子至第803bp之核苷酸片段所轉譯而得者,其中,該IpaB803核苷酸序列編碼為SEQ ID NO:2,所轉譯出之IpaB803蛋白係亦包含一段編碼為KKKL之帶正電之鹼性胺基酸序列。 The IpaB803 protein is obtained by translating the IpaB gene used in the present invention from the ATG start codon to the 803 bp nucleotide fragment, wherein the IpaB803 nucleotide sequence is encoded as SEQ ID NO: 2, which is translated. The IpaB803 protein line also contains a positively charged basic amino acid sequence encoding KKKL.

SHB2308,係為福氏桿菌野生株SH2308之IpaB基因被剔除(knock-out)株。 SHB2308 is a knock-out strain of the IpaB gene of the wild type strain SH2308 of Fusarium.

HCT116,係為人類直腸癌細胞株。 HCT116 is a human rectal cancer cell line.

pFLAG-CMV2,係為一種哺乳動物表現載體,該載體含有CMV2啟動子,以及一旗標序列(FLAG),其中,該旗標序列會與轉殖至質體之5'端結合,而成為一可表現於N端具有旗標標示之蛋白質載體,C端具有組蛋白(His)。 pFLAG-CMV2 is a mammalian expression vector containing a CMV2 promoter and a flag sequence (FLAG), wherein the flag sequence binds to the 5' end of the plastid and becomes a It can be expressed in a protein carrier with a N-terminal flag and a histone (C) at the C-terminus.

pFLAG-CMV2-IpaB,其係藉由遺傳工程技術所構築之重組質體,內含有IpaB基因。 pFLAG-CMV2-IpaB, which is a recombinant plastid constructed by genetic engineering technology, contains the IpaB gene.

pFLAG-CMV2-IpaB803,其係藉由遺傳工程技術所構築之重組質體,內含有IpaB803基因。 pFLAG-CMV2-IpaB803, which is a recombinant plastid constructed by genetic engineering technology, contains the IpaB803 gene.

實例一:構築重組IpaB基因之表現質體 Example 1: Construction of recombinant IpaB gene expression plastid

以聚合酶連鎖反應(Polymerase chain reaction,PCR)分別擴增出一含有IpaB基因片段之產物,以限制酶XbaI、SmaI截切該含有IpaB基因片段之產物以及表現載體pFLAG-CMV2,並進行黏合反應(ligasion),得到一重組質體,如第一圖所示。 A product containing the IpaB gene fragment was amplified by polymerase chain reaction (PCR), and the restriction product XbaI, SmaI was used to cut the product containing the IpaB gene fragment and the expression vector pFLAG-CMV2, and the adhesion reaction was carried out. (ligasion), a recombinant plastid is obtained, as shown in the first figure.

實例二:構築重組IpaB803基因之表現質體 Example 2: Constructing the expression plastid of recombinant IpaB803 gene

步驟同於實例一,先以聚合酶連鎖反應擴增出一含有IpaB803基因片段之產物,再以限制酶XbaI、SmaI截切該含有IpaB803基因片段之產物以及該表現載體pFLAG-CMV2,並進行黏合反應,而得到一重組質體pFLAG-CMV2-IpaB803,如第二圖所示。 The procedure is the same as in the first example. First, a product containing the IpaB803 gene fragment is amplified by a polymerase chain reaction, and the product containing the IpaB803 gene fragment and the expression vector pFLAG-CMV2 are cut and bound by restriction enzymes XbaI and SmaI. The reaction was carried out to obtain a recombinant plasmid pFLAG-CMV2-IpaB803, as shown in the second figure.

實例三:培養HCT116細胞株 Example 3: Culture HCT116 cell line

取冷凍之HCT116細胞株,以37℃水浴槽解凍,將細胞液吸出加入至含有10毫升培養基之10公分培養盤,於37℃、5%二氧化碳之培養箱中進行培養24小時。取出10公分培養盤,去除培養基,再加入新鮮培養基,放回培養箱繼續培養,直至細胞生長至約8~9分滿時,去除培養基,再以5毫升以回溫之磷酸鹽緩衝液(Phosphate Buffered Saline,PBS)沖洗細胞。去除磷酸鹽緩衝液。加入1毫升0.25%胰蛋白酶-乙四胺四醋酸(Trypsin-EDTA,SIGMA,Cat.No.T4799),於37℃下靜置1~2分鐘以懸浮細胞,再加入4毫升培養基終止胰蛋白酶-乙四胺四醋酸之反應,而後打散細胞,作成細胞懸浮液。 The frozen HCT116 cell line was thawed in a 37 ° C water bath, and the cell liquid was aspirated and added to a 10 cm culture plate containing 10 ml of the medium, and cultured in a 37 ° C, 5% carbon dioxide incubator for 24 hours. Remove the 10 cm culture plate, remove the medium, add fresh medium, and return to the incubator to continue the culture until the cells grow to about 8-9 minutes. The medium is removed and 5 ml of the phosphate buffer (Phosphate) is returned. Buffered Saline, PBS) rinse the cells. Remove the phosphate buffer. Add 1 ml of 0.25% trypsin-ethylenetetraminetetraacetic acid (Trypsin-EDTA, SIGMA, Cat. No. T4799), let stand for 1 to 2 minutes at 37 ° C to suspend the cells, and then add 4 ml of medium to stop trypsin - The reaction of ethylenetetraamine tetraacetic acid, and then the cells are broken up to form a cell suspension.

取該細胞懸浮液與培養基之比例為1:3~1:5,使總體積為8毫升,加入10公分培養盤上,放入培養箱進行繼代培養至8~9分滿。而後再以如上述相同方式進行細胞繼代培養到至少第3代,用以供後續實例使用。 The ratio of the cell suspension to the medium was 1:3 to 1:5, and the total volume was 8 ml. The whole volume was added to a 10 cm culture plate and placed in an incubator for subculture until 8 to 9 minutes. The cells are then subcultured to at least passage 3 in the same manner as described above for use in subsequent examples.

實例四:製備pFLAG-CMV2轉染HCT116細胞株 Example 4: Preparation of pFLAG-CMV2 transfected HCT116 cell line

首先,依據lipofectamine 2000(Invitrogen,Cat.No.11668-027)之產品說明書配製一轉殖溶液,備用。 First, a transfer solution was prepared according to the product specification of lipofectamine 2000 (Invitrogen, Cat. No. 11668-027), and was used.

取一管1.5毫升微量離心管,加入2μL、濃度1μg/μL之pFLAG-CMV2質體DNA,再加入48μL之不含血清之細胞培養液(Opti-MEM®I reduced serum medium,Gibco,Cat.No.31985-070),得到一DNA溶液。 Take a 1.5 ml microcentrifuge tube, add 2 μL of pFLAG-CMV2 plastid DNA at a concentration of 1 μg/μL, and add 48 μL of serum-free cell culture medium (Opti-MEM® I reduced serum medium, Gibco, Cat. No). .31985-070), a DNA solution was obtained.

另取一管微量離心管,加入16μL之該轉殖溶液(lipofectamine 2000,Invitrogen公司),再加入34μL不含血清之細胞培養液(Opti-MEM®I reduced serum medium,Gibco,Cat.No.31985-070),得到一lipofectamine混合液,並於室溫靜置5分鐘。 Another tube of microcentrifuge tube was added, 16 μL of the transfer solution (lipofectamine 2000, Invitrogen) was added, and 34 μL of serum-free cell culture medium (Opti-MEM® I reduced serum medium, Gibco, Cat. No. 31985) was added. -070), a lipofectamine mixture was obtained and allowed to stand at room temperature for 5 minutes.

將該lipofectamine混合液全部加入該DNA溶液後,均勻混合,並於室溫靜置20分鐘。 After the lipofectamine mixture was all added to the DNA solution, it was uniformly mixed and allowed to stand at room temperature for 20 minutes.

將實例三中以完成繼代培養之HCT116細胞以培養基稀釋至濃度為1.0 x 105 cells/mL。取一30釐米培養盤,放入兩片玻片,加入1毫升培養基,再加入1毫升細胞懸浮液,放入培養箱,培養48小時,而後加入100μL該轉殖溶液,培養到第4小時,取出該培養盤,去除上清液,加入2毫升培養液(DMEM),再繼續培養一預定時間後,使該pFLAG-CMV2質體轉染HCT116細胞中,供下列實例之用。 The subcultured HCT116 cells in Example 3 were diluted with the medium to a concentration of 1.0 x 10 5 cells/mL. Take a 30 cm culture plate, put two slides, add 1 ml of medium, add 1 ml of cell suspension, put into the incubator, incubate for 48 hours, then add 100 μL of the transfer solution, and culture until the 4th hour. The culture plate was taken out, the supernatant was removed, 2 ml of the culture solution (DMEM) was added, and the culture was continued for a predetermined period of time, and then the pFLAG-CMV2 plasmid was transfected into HCT116 cells for use in the following examples.

實例五:製備pFLAG-CMV2-IpaB轉染HCT116細胞株 Example 5: Preparation of pFLAG-CMV2-IpaB transfected HCT116 cell line

本實例中之步驟大致上如同實例四所述,故不再重複敘述之,惟不同者在於,於本實例中所製備之DNA溶液,係取實例一中之pFLAG-CMV2-IpaB重組質體DNA,加入48μL之不含血清之細胞培養液(Opti-MEM®I reduced serum medium,Gibco,Cat.No.31985-070)所製備,用以使pFLAG-CMV2-IpaB轉染HCT116細胞株。 The steps in this example are substantially as described in Example 4, and therefore will not be repeated, except that the DNA solution prepared in this example is the recombinant plasmid DNA of pFLAG-CMV2-IpaB in Example 1. 48 μL of serum-free cell culture medium (Opti-MEM® I reduced serum medium, Gibco, Cat. No. 31985-070) was added to transfect the pFLAG-CMV2-IpaB into the HCT116 cell line.

實例六:製備pFLAG-CMV2-IpaB803轉染HCT116細胞株 Example 6: Preparation of pFLAG-CMV2-IpaB803 transfected HCT116 cell line

本實例中之步驟大致上如同實例四所述,故於此不再次說明,惟,不同者在於本實例中所製備之DNA溶液,係取實例二中之pFLAG-CMV2-IpaB803重組質體DNA,加入48μL之不含血清之細胞培養液(Opti-MEM®I reduced serum medium,Gibco,Cat.No.31985-070)所製備,用以使pFLAG-CMV2-IpaB803轉染HCT116細胞株。 The steps in this example are substantially as described in Example 4, and therefore will not be described again. However, the DNA solution prepared in this example differs from the recombinant plasmid DNA of pFLAG-CMV2-IpaB803 in Example 2. 48 μL of serum-free cell culture medium (Opti-MEM® I reduced serum medium, Gibco, Cat. No. 31985-070) was added to transfect pFLAG-CMV2-IpaB803 into HCT116 cell line.

實例七:IpaB基因/IpaB803基因於HCT116細胞中表現 Example 7: IpaB gene/IpaB803 gene expressed in HCT116 cells

取實例四至實例六中已完成轉染之HCT116細胞,分為三組,其中,第1組係為實例四中所製備之pFLAG-CMV2轉染HCT116細胞;第2組係為實例五所製備之pFLAG-CMV2-IpaB轉染HCT116細胞;第3組係為實例六所製備之pFLAG-CMV2-IpaB803轉染HCT116細胞。 The transfected HCT116 cells from Example 4 to Example 6 were divided into three groups, wherein the first group was the pFLAG-CMV2 transfected HCT116 cells prepared in Example 4; the second group was the pFLAG prepared in Example 5. - CMV2-IpaB was transfected into HCT116 cells; the third group was transfected with pFLAG-CMV2-IpaB803 prepared in Example VI.

將各該組細胞分別培養24小時後,再分別將各該組細胞同時以細胞核螢光染色劑(DAPI)、抗標誌(anti-FLAG)抗體及粒線體螢光染色劑(mito-tracker)進行螢光染色,並以倒立式共軛焦點顯微鏡,於不同激發波長下觀察各組之細胞,結果如附件一至三所示。 After culturing each group of cells for 24 hours, each group of cells was simultaneously subjected to nuclear fluorescent staining agent (DAPI), anti-FLAG antibody and mitochon fluorescent staining agent (mito-tracker). Fluorescent staining was performed, and cells of each group were observed at different excitation wavelengths by an inverted conjugate focus microscope, and the results are shown in Annexes I to III.

附件一至三依序分別係為第1組至第3組之結果圖,詳言之:各該附件之A圖係為明亮視野下所觀察之細胞型態;各該附件之B圖係為細胞核螢光染色劑(DAPI)螢光染色之結果,各圖中顯示藍色之部位為細胞核;各該附件之C圖係為抗標誌(anti-FLAG)抗體螢光染色之結果,各圖中綠色部位係為偵測到IpaB-FLAG融合蛋白或是IpaB803-FLAG 融合蛋白之處;各該附件之D圖係為粒線體螢光染色劑(mito-tracker)螢光染色之結果,各圖中紅色部位係為粒線體;各該附件之E圖係為各該附件之B圖至D圖螢光染色重疊之結果,藍色與綠色重疊部位係呈淺藍色,表示IpaB-FLAG融合蛋白或是IpaB803-FLAG融合蛋白進入到細胞核中,紅色與綠色皆出現之部位係表示IpaB-FLAG融合蛋白或是IpaB803-FLAG融合蛋白於細胞質中表現;各該附件之F圖係為各該附件之A圖中白色方框之放大圖;各該附件之G圖係為各該附件之B圖中白色方框之放大圖;各該附件之H圖係為各該附件之C圖中白色方框之放大圖;各該附件之I圖係為各該附件之D圖中白色方框之放大圖;各該附件之J圖係為各該附件之E圖中白色方框之放大圖;其中,各該附件之F圖至J圖放大倍率分別為1200倍。 The results of the first to third groups are the results of the first group to the third group. In detail, the A picture of each attachment is the cell type observed under the bright field of view; the B picture of each accessory is the nucleus The result of fluorescent staining of fluorescent staining agent (DAPI), the blue part is the nucleus in each figure; the C picture of each accessory is the result of fluorescent staining of anti-FLAG antibody, green in each figure The site is the detection of IpaB-FLAG fusion protein or IpaB803-FLAG The fusion protein; the D picture of each accessory is the result of fluorescent staining of the mitochon fluorescent dye (mito-tracker), the red part of each figure is a mitochondria; the E picture of each accessory is The results of the overlapping of the fluorescent staining of the B to D of the annex, the blue and green overlapping parts are light blue, indicating that the IpaB-FLAG fusion protein or the IpaB803-FLAG fusion protein enters the nucleus, both red and green. The appearance of the part indicates the expression of the IpaB-FLAG fusion protein or the IpaB803-FLAG fusion protein in the cytoplasm; the F map of each attachment is an enlarged view of the white square in the A of each attachment; the G map of each attachment An enlarged view of the white squares in Figure B of each of the attachments; each of the attachments H is an enlarged view of the white squares in Figure C of each of the attachments; each of the attachments is shown in Figure I. A magnified view of the white box in the figure D; each of the J diagrams of the attachment is an enlarged view of the white box in the E diagram of each attachment; wherein the magnifications of the F to J diagrams of the attachments are respectively 1200 times.

由附件一至附件三之結果比對可知,不論是IpaB基因或是IpaB803基因,皆可經由轉染進入細胞中,並分別於細胞質或/及細胞核中表現IpaB蛋白或是IpaB803蛋白。 From the results of Annexes I to III, it can be seen that both the IpaB gene and the IpaB803 gene can be transfected into cells and express IpaB protein or IpaB803 protein in the cytoplasm or/and nucleus, respectively.

實例八:製備SHB2308菌液 Example 8: Preparation of SHB2308 bacterial solution

將菌株SHB2308接種LB培養基(LB broth)上,37℃培養隔夜。取100μL SHB2308菌液加入含900μL之M9溶液之微量離心管中,連續稀釋到10-7,然後將10-6與10-7兩個稀釋度之SHB2308菌液中取出100μL塗抹到LB培養基,進行細胞計數,剩下之SHB2308菌液放到4 ℃冰箱內保存。隔天計算菌落總數指標(colony-forming unit,CFU)值,並推算原SHB2308菌液濃度,再取保存於4℃冰箱中之SHB2308菌液於室溫中回溫。取1ml SHB2308菌液於室溫以12000rpm離心5分鐘,移除上清液後,再以1 ml不含胎牛血清之細胞培養基(DMEM)重新懸浮細胞沈澱物(cell pellet),並得以不含胎牛血清的細胞培養基稀釋(DMEM)SHB2308菌液至濃度為1x107 CFU/mL,供下列實例使用。 The strain SHB2308 was inoculated on LB medium (LB broth) and cultured overnight at 37 °C. 100 μL of SHB2308 broth was added to a microcentrifuge tube containing 900 μL of M9 solution, serially diluted to 10 -7 , and then 100 μL of 10 -6 and 10 -7 two dilutions of SHB2308 broth was applied to LB medium. The cells were counted, and the remaining SHB2308 broth was stored in a refrigerator at 4 °C. The colony-forming unit (CFU) value was calculated every other day, and the concentration of the original SHB2308 bacteria solution was calculated, and the SHB2308 bacteria solution stored in the refrigerator at 4 °C was taken back to room temperature. Take 1 ml of SHB2308 bacteria solution and centrifuge at 12000 rpm for 5 minutes at room temperature. After removing the supernatant, resuspend the cell pellet in 1 ml of cell culture medium (DMEM) containing no fetal bovine serum. The fetal culture medium was diluted with cell culture medium (DMEM) SHB2308 to a concentration of 1×10 7 CFU/mL for use in the following examples.

實例九:製備大腸桿菌菌株DH5 α菌液 Example 9: Preparation of Escherichia coli strain DH5 α bacterial solution

本實例步驟係大致相同於實例八所述,因此,不再加以贅述,惟不同者在於本實例係取大腸桿菌菌株DH5 α接種於培養基上,而得到濃度為1x107 CFU/mL之大腸桿菌菌株DH5 α菌液,供下列實例使用,其中,大腸桿菌菌株DH5 α係由轉染而得表現增強型綠色螢光蛋白(enhanced green fluorescent protein;EGFP)。 The steps of this example are substantially the same as those described in Example 8, and therefore, no further description is given, except that the present example is obtained by inoculating the Escherichia coli strain DH5α on the medium to obtain an Escherichia coli strain having a concentration of 1×10 7 CFU/mL. The DH5 alpha bacterial solution was used in the following examples, wherein the Escherichia coli strain DH5α was transfected to express enhanced green fluorescent protein (EGFP).

實例十:共同培養菌株SHB2308與HCT116細胞株 Example 10: Co-cultivating strains SHB2308 and HCT116 cell lines

分別取實例四至實例六所製備已轉染質體之細胞株,並分為三組,其中:第1組係為pFLAG-CMV2轉染HCT116細胞株,作為對照組;第2組係為pFLAG-CMV2-IpaB轉染HCT116細胞株;第3組係為pFLAG-CMV2-IpaB803轉染HCT116細胞株。 The cell lines of the transfected plastids prepared in Examples 4 to 6 were respectively divided into three groups, wherein: the first group was pFLAG-CMV2 transfected HCT116 cell line as a control group; the second group was pFLAG- CMV2-IpaB was transfected into HCT116 cell line; the third group was transfected with pFLAG-CMV2-IpaB803 into HCT116 cell line.

以下為本實例所採用共同培養的步驟,先以第1組為例作為說明。 The following is the procedure for co-cultivation used in the present example, and the first group is taken as an example for illustration.

首先,取第1組之細胞懸浮液,以培養液(DMEM)稀釋細胞濃度為1.0 x105cells/mL。再取一30釐米培養盤,放入兩片玻片及加入1 毫升培養液(DMEM),之後再加入第1組之1毫升細胞懸浮液,放回培養箱,培養48小時。取出該30釐米培養盤,去除培養液(DMEM),用1毫升磷酸鹽緩衝溶液清洗。而後加入實例八中所製備濃度為1x107 CFU/mL SHB2308菌液1毫升,其中,感染複數(Multiplicity of infection,MOI)為100,再以速度1600 rpm,離心5分鐘,於細胞培養箱培養20分鐘,去除上清液,並用1毫升之磷酸鹽緩衝溶液清洗三次,加入不含胎牛血清之培養液(DMEM)繼續培養4小時。 First, the cell suspension of the first group was taken, and the cell concentration was diluted to 1.0 x 10 5 cells/mL in a culture medium (DMEM). Take a 30 cm culture plate, place two slides and add 1 ml of culture medium (DMEM), then add 1 ml of the cell suspension of the first group, put it back into the incubator, and incubate for 48 hours. The 30 cm culture dish was taken out, the culture solution (DMEM) was removed, and it was washed with 1 ml of a phosphate buffer solution. Then eight prepared in Example was added at a concentration of 1x10 7 CFU / mL SHB2308 bacterial solution 1 ml, wherein the MOI (Multiplicity of infection, MOI) of 100, at a rate of 1600 rpm, centrifuged for 5 minutes in a cell incubator 20 Minutes, the supernatant was removed and washed three times with 1 ml of phosphate buffer solution, and cultured for 4 hours in a medium containing no fetal bovine serum (DMEM).

第2組與第3組亦分別取實例五及六中已轉染好之細胞株,依據上述步驟,而分別與SHB2308菌液進行共同培養4小時。 Groups 2 and 3 also took the transfected cell lines of Examples 5 and 6, respectively, and co-cultured with SHB2308 solution for 4 hours according to the above steps.

進行共同培養4小時後,分別對第1組至第3組之HCT116細胞進行免疫螢光染色,其中,所採用之抗體為抗志賀氏菌(anti-shigella)抗體以及細胞核螢光染色劑(DAPI),並以倒立式共軛焦點顯微鏡,於不同激發波長下觀察各組之細胞,結果如附件四至六所示。 After co-culture for 4 hours, immunofluorescence staining of HCT116 cells of Groups 1 to 3 was performed, respectively, wherein the antibodies used were anti-shigella antibodies and nuclear fluorescent stains (DAPI). The cells of each group were observed at different excitation wavelengths by an inverted conjugate focus microscope, and the results are shown in Annexes 4 to 6.

附件四至六分別依序係為第1組至第3組之結果圖,詳言之:各該附件之A圖係為明亮視野下所觀察之細胞型態;各該附件之B圖係為細胞核螢光染色劑(DAPI)螢光染色之結果,各圖中顯示藍色之部位為細胞核;各該附件之C圖係為抗志賀氏菌抗體進行免疫螢光染色之結果,各圖中綠色部位係為偵測到菌株SHB2308之處;各該附件之D圖係為各該附件之B圖及C圖螢光染色重疊之結果,淡藍色部位係表示菌株SHB2308位於細胞核中;各該附件之E圖係為各該附件之A圖中白色方框之放大圖; 各該附件之F圖係為各該附件之B圖中白色方框之放大圖;各該附件之G圖係為各該附件之C圖中白色方框之放大圖;各該附件之H圖係為各該附件之D圖中白色方框之放大圖;其中,各該附件之E圖至H圖之放大倍率分別為1200倍。 Annexes 4 to 6 are the results of groups 1 to 3, respectively. In detail, the A map of each annex is the cell type observed in the bright field of view; the B picture of each annex is the nucleus The result of fluorescent staining of fluorescent staining agent (DAPI), the blue part is the nucleus in each figure; the C picture of each accessory is the result of immunofluorescence staining of anti-Shigella antibody, the green part of each figure The strain SHB2308 was detected; the D map of each accessory is the result of overlapping the fluorescence staining of the B and C pictures of each accessory, and the light blue part indicates that the strain SHB2308 is located in the nucleus; E is an enlarged view of the white box in the A diagram of each of the attachments; The F diagram of each attachment is an enlarged view of the white box in the B diagram of each attachment; the G diagram of each attachment is an enlarged view of the white box in the C diagram of each attachment; the H diagram of each attachment It is an enlarged view of the white box in the D picture of each accessory; wherein the magnification of each of the attachments from E to H is 1200 times.

觀察附件四之各圖,菌株SHB2308僅於細胞外被偵測到,而觀察附件五及六之各圖,顯示呈現綠色之菌株SHB2308係存在於細胞質中,並於各圖細胞核中淡藍色部位顯示之菌株SHB2308存在於細胞核中。換言之,比對附件四至六之結果,可知未帶有IpaB基因或IpaB803基因之pFLAG-CMV2質體所轉染之HCT116細胞,與菌株SHB2308共同培養後,菌株SHB2308僅能於細胞膜外被偵測到,而未能進入細胞中,如附件四所示;而不論是轉染重組質體pFLAG-CMV2-IpaB之HCT116細胞,或轉染重組質體pFLAG-CMV2-IpaB803之HCT116細胞,菌株SHB2308共同培養後,皆能於細胞質或/及細胞核中發現菌株SHB2308存在,分別如附件五及附件六所示。 Observing the maps in Annex IV, strain SHB2308 was detected only outside the cell, and observation of the maps of Annexes 5 and 6 showed that the green strain SHB2308 was present in the cytoplasm and was light blue in the nucleus of each figure. The strain SHB2308 shown was present in the nucleus. In other words, comparing the results of Annexes 4 to 6, it is known that HCT116 cells transfected with pFLAG-CMV2 plastid without IpaB gene or IpaB803 gene, after co-culture with strain SHB2308, strain SHB2308 can only be detected outside the cell membrane. , but failed to enter the cell, as shown in Annex IV; whether it is HCT116 cells transfected with recombinant plastid pFLAG-CMV2-IpaB, or HCT116 cells transfected with recombinant plastid pFLAG-CMV2-IpaB803, co-cultured with strain SHB2308 Afterwards, strain SHB2308 can be found in the cytoplasm or/and nucleus, as shown in Annexes 5 and 6 respectively.

實例十一:共同培養大腸桿菌菌株DH5 αα與HCT116細胞株 Example 11: Co-cultivation of Escherichia coli strain DH5 αα and HCT116 cell line

分別取實例四至實例六所製備已轉染質體之細胞株,並分為三組,其中:第1組係為pFLAG-CMV2轉染HCT116細胞株,作為對照組;第2組係為pFLAG-CMV2-IpaB轉染HCT116細胞株;第3組係為pFLAG-CMV2-IpaB803轉染HCT116細胞株。 The cell lines of the transfected plastids prepared in Examples 4 to 6 were respectively divided into three groups, wherein: the first group was pFLAG-CMV2 transfected HCT116 cell line as a control group; the second group was pFLAG- CMV2-IpaB was transfected into HCT116 cell line; the third group was transfected with pFLAG-CMV2-IpaB803 into HCT116 cell line.

如同實例十中所述共同培養之步驟,而取實例九中所製備好濃度為1x107 CFU/mL之大腸桿菌菌株DH5 α菌液,分別與第1組至第3 組之HCT116細胞進行共同培養4小時。 E. coli strain DH5 α prepared at a concentration of 1×10 7 CFU/mL prepared in Example 9 was co-cultured with HCT116 cells of Groups 1 to 3, respectively, as in the co-cultivation step described in Example 10. 4 hours.

進行共同培養4小時後,分別對第1組至第3組之HCT116細胞以細胞核螢光染色劑(DAPI)免疫螢光染色,並以倒立式共軛焦點顯微鏡,於不同激發波長下觀察各組之細胞,結果如附件七至九所示。 After co-cultivation for 4 hours, HCT116 cells from group 1 to group 3 were stained with immunofluorescence staining with nuclear fluorescent staining (DAPI), and the groups were observed at different excitation wavelengths by inverted conjugate focus microscope. The results of the cells are shown in Annexes VII to IX.

附件七至九分別依序係為第1組至第3組之結果圖,詳言之:各該附件之A圖係為明亮視野下所觀察之細胞型態;各該附件之B圖係為細胞核螢光染色劑(DAPI)螢光染色之結果,各圖中顯示藍色之部位為細胞核;各該附件之C圖綠色螢光係為偵測大腸桿菌菌株DH5 α表現增強型綠色螢光蛋白之結果,換言之,各圖中綠色部位係為偵測到大腸桿菌菌株DH5 α處;各該附件之D圖係為各該附件之B圖及C圖螢光染色重疊之結果,其中,藍色與綠色之重疊部位係呈淡藍色,表示該大腸桿菌菌株DH5 α位於細胞核中;各該附件之E圖係為各該附件之A圖中白色方框之放大圖;各該附件之F圖係為各該附件之B圖中白色方框之放大圖;各該附件之G圖係為各該附件之C圖中白色方框之放大圖;各該附件之H圖係為各該附件之D圖中白色方框之放大圖;其中,其中,各該附件之E圖至H圖之放大倍率分別為1200倍。 Annexes VII to IX are respectively the result maps of Groups 1 to 3, in detail: each of the attachments A is a cell type observed under a bright field of view; The result of fluorescent staining of nuclear fluorescent staining agent (DAPI), the blue part is the nucleus in each figure; the green fluorescent system of the C picture of each accessory is the enhanced green fluorescent protein of E. coli strain DH5 α As a result, in other words, the green part in each figure is detected as E. coli strain DH5 α; the D picture of each accessory is the result of overlapping of the B and C pictures of each of the attachments, among them, blue The overlapping part with green is light blue, indicating that the E. coli strain DH5 α is located in the nucleus; the E map of each attachment is an enlarged view of the white box in the A picture of each attachment; It is an enlarged view of the white box in the B picture of each attachment; the G picture of each attachment is an enlarged view of the white box in the C picture of each attachment; the H picture of each attachment is the attachment of each An enlarged view of the white box in the figure D; wherein, the enlargement of the E to H of each of the attachments Rates were 1200 times.

觀察附件七之各圖,大腸桿菌菌株DH5 α僅於細胞外被偵測到,而觀察附件八及九之各圖,顯示呈現綠色之大腸桿菌菌株DH5 α係存在於細胞質中,並於各圖細胞核中淡藍色部位顯示之大腸桿菌菌株 DH5 α存在於細胞核中。換言之,比對附件七至九之結果可知,經由未帶有IpaB基因或IpaB803基因之pFLAG-CMV2質體所轉染之HCT116細胞,與大腸桿菌菌株DH5 α培養後,僅能於細胞膜外偵測到大腸桿菌菌株DH5 α存在,如附件七所示;而不論是轉染重組質體pFLAG-CMV2-IpaB之HCT116細胞,或轉染重組質體pFLAG-CMV2-IpaB803之HCT116細胞株,與具有大腸桿菌菌株DH5 α培養後,皆能於細胞質或/及細胞核發現大腸桿菌菌株DH5 α存在,如附件八及附件九所示。 Observing the maps in Annex VII, E. coli strain DH5 α was detected only outside the cell, and each of the figures in Annexes 8 and 9 was observed, showing that the green E. coli strain DH5 α was present in the cytoplasm, and E. coli strain displayed in light blue part of the nucleus DH5 alpha is present in the nucleus. In other words, comparing the results of Annexes VII to IX, it is known that HCT116 cells transfected with pFLAG-CMV2 plastid without IpaB gene or IpaB803 gene can only be detected outside the cell membrane after incubation with E. coli strain DH5α. To E. coli strain DH5 α, as shown in Annex VII; whether it is HCT116 cells transfected with recombinant plastid pFLAG-CMV2-IpaB, or HCT116 cell line transfected with recombinant plastid pFLAG-CMV2-IpaB803, with large intestine After culture of Bacillus strain DH5 α, E. coli strain DH5 α can be found in the cytoplasm or/and nucleus, as shown in Annex VIII and Annex IX.

藉由上述各該實例之結果可知,本發明所提供調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法,其係利用IpaB基因或是IpaB803基因轉染細胞,並使IpaB基因或是IpaB803基因於細胞內表現IpaB蛋白或是IpaB803蛋白,藉此,使大分子如實例中所述菌株SHB2308或大腸桿菌菌株DH5 α得以由細胞外進入細胞內,甚而進入到細胞核內。簡言之,藉由本發明所揭技術內容及其特徵,係得使大分子得以進入能表現IpaB基因或是及IpaB基因衍生產物之真核細胞之細胞質或/及細胞核中,進而將此應用於生醫藥學等發展領域中。 As can be seen from the results of the above examples, the method for regulating the entry of macromolecules into cells and the method for regulating the entry of macromolecules into cells by the present invention utilizes IpaB gene or IpaB803 gene to transfect cells and make IpaB gene. Or the IpaB803 gene expresses the IpaB protein or the IpaB803 protein in the cell, whereby the macromolecule such as the strain SHB2308 or the Escherichia coli strain DH5α as described in the example can be introduced into the cell from the outside of the cell, and even into the nucleus. Briefly, the technical content and characteristics of the present invention enable the macromolecule to enter the cytoplasm or/and the nucleus of a eukaryotic cell capable of expressing the IpaB gene or the IpaB gene-derived product, and further apply this. In the field of development such as biomedicine.

第一圖係為pFLAG-CMV2-IpaB重組質體之圖譜。 The first panel is a map of the recombinant plasmid of pFLAG-CMV2-IpaB.

第二圖係為pFLAG-CMV2-IpaB803重組質體之圖譜。 The second figure is a map of the recombinant plasmid of pFLAG-CMV2-IpaB803.

附件一係為pFLAG-CMV2轉染HCT116細胞,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗標誌(anti-FLAG)抗體螢光染色之結果;D圖為粒線體螢光染色劑(mito-tracker)螢光染色之結果;E圖為B圖至D圖螢光染色重疊之結果。 Annex I is a cell map of pCT-CMV2 transfected HCT116 cells, observed by inverted conjugated focal microscope through immunostaining, wherein A is the cell type observed under bright field; B is nuclear fluorescein The result of fluorescent staining of dye (DAPI); C is the result of fluorescent staining of anti-FLAG antibody; D is the result of fluorescent staining of mitochon fluorescent dye (mito-tracker); The picture shows the results of the overlapping of fluorescent staining from B to D.

附件二係為pFLAG-CMV2-IpaB轉染HCT116細胞,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗標誌(anti-FLAG)抗體螢光染色之結果;D圖為粒線體螢光染色劑(mito-tracker)螢光染色之結果;E圖為B圖至D圖螢光染色重疊之結果。 Annex II is the cell image of the HCT116 cells transfected with pFLAG-CMV2-IpaB by immunofluorescence and observed by inverted conjugated focal microscope. The A picture is the cell type observed under bright field; the B picture is the cell nucleus. The result of fluorescent staining of fluorescent staining agent (DAPI); the picture C is the result of fluorescent staining of anti-FLAG antibody; D is the result of fluorescent staining of mitochon fluorescent dye (mito-tracker) ; E is the result of overlapping of fluorescent staining from B to D.

附件三係為pFLAG-CMV2-IpaB803轉染HCT116細胞,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗標誌(anti-FLAG)抗體螢光染色之結果;D圖為粒線體螢光染色劑(mito-tracker)螢光染色之結果;E圖為B圖至D圖螢光染色重疊之結果。 Annex III is a cell map of pCT-CMV2-IpaB803 transfected HCT116 cells, observed by inverted conjugated focal microscope through immunostaining, wherein A is the cell type observed under bright field; B is the nucleus The result of fluorescent staining of fluorescent staining agent (DAPI); the picture C is the result of fluorescent staining of anti-FLAG antibody; D is the result of fluorescent staining of mitochon fluorescent dye (mito-tracker) ; E is the result of overlapping of fluorescent staining from B to D.

附件四係為pFLAG-CMV2轉染HCT116細胞並於菌株SHB2308共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗志賀氏菌抗體螢光染色之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex IV is a cell map observed by inverted conjugated focal microscope after transfecting HCT116 cells with pFLAG-CMV2 and co-cultivating with strain SHB2308 by immunostaining, wherein A is the cell type observed under bright field of view. B is the result of fluorescent staining of nuclear fluorescent staining agent (DAPI); C is the result of fluorescent staining of anti-Shigella antibody; and D is the result of overlapping of fluorescent staining of B to C.

附件五係為pFLAG-CMV2-IpaB轉染HCT116細胞並於菌株 SHB2308共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗志賀氏菌抗體螢光染色之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex V is a transfected HCT116 cell with pFLAG-CMV2-IpaB and the strain After co-cultivation of SHB2308, immunofluorescence, cell diagram observed by inverted conjugated focal microscope, wherein A is the cell type observed in the bright field; B is the nuclear fluorescent stain (DAPI) fluorescence The result of staining; C is the result of fluorescent staining of anti-Shigella antibody; D is the result of overlapping of fluorescent staining of B to C.

附件六係為pFLAG-CMV2-IpaB803轉染HCT116細胞並於菌株SHB2308共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為抗志賀氏菌抗體螢光染色之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex VI is a cell map of inverted conjugated focal microscope observed by transfected HCT116 cells with pFLAG-CMV2-IpaB803 and co-cultured with strain SHB2308 by immunostaining, wherein A is a cell observed under bright field of view. Type B; the result of fluorescent staining of nuclear fluorescent staining agent (DAPI); C is the result of fluorescent staining of anti-Shigella antibody; and D is the result of overlapping of fluorescent staining of B to C.

附件七係為pFLAG-CMV2轉染HCT116細胞並於大腸桿菌菌株DH5 α共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為偵測大腸桿菌菌株DH5 α表現增強型綠色螢光蛋白之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex VII is a cell map observed by inverted inverted conjugated focal microscope after transfecting HCT116 cells with pFLAG-CMV2 and co-cultivating with E. coli strain DH5α by immunostaining, wherein A is observed under bright field of view. Cell type; B picture is the result of fluorescent staining of nuclear fluorescent staining agent (DAPI); C picture is the result of detecting enhanced green fluorescent protein of E. coli strain DH5 α; D picture is B to C The result of overlapping light staining.

附件八係為pFLAG-CMV2-IpaB轉染HCT116細胞並於大腸桿菌菌株DH5 α共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為偵測大腸桿菌菌株DH5 α表現增強型綠色螢光蛋白之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex VIII is the cell map of pFLAG-CMV2-IpaB transfected HCT116 cells and co-cultured with E. coli strain DH5α, and observed by inverted conjugated focal microscope through immunostaining, wherein A is a bright field of view. Observed cell type; B picture is the result of fluorescent staining of nuclear fluorescent staining agent (DAPI); C picture is the result of detecting enhanced green fluorescent protein of E. coli strain DH5 α; D picture is B to C Figure shows the result of overlapping fluorescent staining.

附件九係為pFLAG-CMV2-IpaB803轉染HCT116細胞並於大腸桿菌菌株DH5 α共同培養後,經由免疫染色,以倒立式共軛焦顯微鏡所觀察之細胞圖,其中,A圖為明亮視野下所觀察之細胞型態;B圖為細胞核螢光染色劑(DAPI)螢光染色之結果;C圖為偵測大腸桿菌菌株DH5 α表現增強型綠色螢光蛋白之結果;D圖為B圖至C圖螢光染色重疊之結果。 Annex IX is the cell map of pFLAG-CMV2-IpaB803 transfected with HCT116 cells and co-cultured with E. coli strain DH5α, and observed by inverted conjugated focal microscope through immunostaining, wherein A is a bright field of view. Observed cell type; B picture is the result of fluorescent staining of nuclear fluorescent staining agent (DAPI); C picture is the result of detecting enhanced green fluorescent protein of E. coli strain DH5 α; D picture is B to C Figure shows the result of overlapping fluorescent staining.

<110> 國立中興大學 <110> National Chung Hsing University

<120> 調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法 <120> A protein that regulates the entry of macromolecules into cells and a method for regulating the entry of macromolecules into cells

<160> 2 <160> 2

<170> PatentIn version3.3 <170> PatentIn version3.3

<210> 1 <210> 1

<211> 1743 <211> 1743

<212> DNA <212> DNA

<213> Shigella flexneri <213> Shigella flexneri

<400> 1 <400> 1

<210> 2 <210> 2

<211> 803 <211> 803

<212> DNA <212> DNA

<213> Shigella flexneri <213> Shigella flexneri

<400> 2 <400> 2

Claims (7)

一種使大分子進入細胞內之方法,係包含有下列步驟:A.構築一重組質體,具有一外源基因,得用以表現至少包含有一段帶正電之鹼性胺基酸序列之蛋白,該胺基酸序列編碼為KKKL;B.將該重組質體轉殖至一真核細胞內,而使該外源基因於該真核細胞內表現;C.選取一大分子,與步驟B中之該真核細胞共同培養;D.該大分子進入到該細胞內。 A method for introducing a macromolecule into a cell comprises the steps of: A. constructing a recombinant plastid having an exogenous gene for expressing a protein comprising at least a positively charged basic amino acid sequence The amino acid sequence is encoded as KKKL; B. the recombinant plastid is transferred into a eukaryotic cell, and the foreign gene is expressed in the eukaryotic cell; C. selecting a large molecule, and step B The eukaryotic cells are co-cultured; D. the macromolecule enters the cell. 依據申請專利範圍第1項所述使大分子進入細胞內之方法,其中,步驟A中該外源基因選自由IpaB基因及IpaB基因衍生產物所組成之群。 The method for introducing a macromolecule into a cell according to the first aspect of the patent application, wherein the exogenous gene in the step A is selected from the group consisting of the IpaB gene and the IpaB gene-derived product. 依據申請專利範圍第1或2項所述使大分子進入細胞內之方法,其中,該步驟D中,該大分子係為一細菌。 A method for introducing a macromolecule into a cell according to claim 1 or 2, wherein in the step D, the macromolecular system is a bacterium. 依據申請專利範圍第3項所述使大分子進入細胞內之方法,其中,該步驟D中,該細菌係進入該細胞之細胞核內。 A method for introducing a macromolecule into a cell according to the third aspect of the patent application, wherein in the step D, the bacterium enters the nucleus of the cell. 一種依據申請專利範圍第3項所述使大分子進入細胞內之方法,其中,該步驟D中,該細菌係進入該細胞之細胞質內。 A method for introducing a macromolecule into a cell according to the third aspect of the patent application, wherein in the step D, the bacterium enters the cytoplasm of the cell. 一種調控大分子進入細胞內之蛋白質,其胺基酸序列係少包含一段帶正電之鹼性胺基酸序列,編碼為KKKL。 A protein that regulates the entry of macromolecules into a cell, the amino acid sequence of which contains less than a positively charged basic amino acid sequence encoded as KKKL. 依據申請專利範圍第6項所述調控大分子係入細胞內之蛋白質,其係由選自於由IpaB基因及IpaB基因衍生產物所組成之群中之一基因所轉譯而成者。 The protein which regulates the macromolecule into the cell according to the sixth aspect of the patent application is translated from a gene selected from the group consisting of the IpaB gene and the IpaB gene-derived product.
TW101134035A 2012-09-17 2012-09-17 Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells TWI472617B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW101134035A TWI472617B (en) 2012-09-17 2012-09-17 Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW101134035A TWI472617B (en) 2012-09-17 2012-09-17 Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells

Publications (2)

Publication Number Publication Date
TW201412985A true TW201412985A (en) 2014-04-01
TWI472617B TWI472617B (en) 2015-02-11

Family

ID=53018591

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101134035A TWI472617B (en) 2012-09-17 2012-09-17 Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells

Country Status (1)

Country Link
TW (1) TWI472617B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495330B1 (en) * 2002-04-12 2009-01-21 O'Dowd, Brian, F. Method of identifying transmembrane protein-interacting compounds
TWI365882B (en) * 2007-06-15 2012-06-11 Univ Nat Chunghsing Shigella ipab803 protein, producing method and coding nucleic acid thereof

Also Published As

Publication number Publication date
TWI472617B (en) 2015-02-11

Similar Documents

Publication Publication Date Title
EP2589377B1 (en) Microvesicles derived from cell protoplast, and use thereof
WO2018067546A1 (en) Delivery of therapeutic rnas via arrdc1-mediated microvesicles
KR20210131991A (en) Compositions and methods for compartment-specific cargo delivery
JP2016519933A (en) In vitro generation of red blood cells with sortable proteins
US20210379192A1 (en) Skeletal muscle targeting moieties and uses thereof
CN102596179A (en) Liposomal compositions and uses of same
EP4135665A2 (en) Modular binding proteins for extracellular vesicles and uses thereof
WO2022078310A1 (en) Novel piggybac transposon system and use thereof
WO2022262130A1 (en) Macrophage specific chimeric antigen receptor, controllable polarized monocyte/macrophage expressing receptor, preparation method therefor and application thereof
CN112839671A (en) Drug resistant immune cells and methods of use thereof
CN111954684A (en) CAR-T cells and autoimmune diseases
JP2023514975A (en) Non-Naturally Occurring Vesicles Containing Chimeric Vesicle Localizing Moieties, Methods of Their Production, and Uses Thereof
CN114786685A (en) Mitochondria-based drug delivery system and application thereof
US11702462B2 (en) Gene transfer systems for stem cell engineering
US10472408B2 (en) Fusion proteins comprising partial tetraspanin sequences and a system thereof for presenting peptides on the cell surface
WO2018043716A1 (en) Method for obtaining eukaryote cell capable of expressing gas vesicle protein complex, eukaryote cell, method for producing gas vesicle protein complex using eukaryote cell, and kit
CN114008205A (en) Leader sequence
TWI472617B (en) Protein for regulation of macromolecules into cells and method for regulation of macromolecules into cells
KR101647491B1 (en) Auto-Cell Concentration Recognition Auto-Inducible Expression System For Which Inducer Is Not Required and Use Thereof
Zare et al. Genetically engineered E. coli invade epithelial cells and transfer their genetic cargo into the cells: an approach to a gene delivery system
US20170362279A1 (en) Vlp with a fusion protein
TWI515203B (en) Nuclear localization signal peptides derived from vp2 protein of chicken anemia virus and uses of said peptides
KR20170033559A (en) Novel fusion peptides for gene delivery
WO2020006675A1 (en) Method for in vitro reprogramming of fibroblasts into sertoli cells and application thereof
CN110229849A (en) Spatiotemporal database type uPA gene expression non-virus carrier and its preparation method and application

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees